Jade Biosciences
JBIO
13.77
+0.36
+2.68%
Jade Biosciences
US · JBIO
#3338 by market cap
Listed 2021
13.77
+0.36
+2.68%
Live - 5344 symbols - heartbeat 281s ago
· 2026-10-08 08:46
Pre-market
13.30
-3.41%
After-hours
13.00
-5.59%
- Market cap
- 875.74M
- P/E (TTM)i
- -12.87
- P/Bi
- 1.99
- EPSi
- -3.19
- Div yieldi
- 0.00%
- 52W posi
- 28%
Reader sentiment
Are you bullish or bearish on JBIO?
Anonymous reader poll. Unscientific, not investment advice.
Revenue annual, last 2 years
Income statement
| Line item | 2024 | 2025 |
|---|---|---|
| Revenue | -- | -- |
| Gross profit | -- | -- |
| Selling & admin expenses | -- | 20.42M |
| Research & development | -- | 93.12M |
| Operating profit | -- | -113.54M |
| Pretax profit | -- | -127.35M |
| Tax | -- | 58.00K |
| Net profit | -- | -127.41M |
| Basic EPS | -- | -3 |
| Diluted EPS | -- | -3.19 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 3.36M | 5.23M | 5.39M | 6.44M | 7.39M | 8.85M |
| Research & development | 20.02M | 22.55M | 22.01M | 28.54M | 36.05M | 50.07M |
| Operating profit | -23.38M | -27.78M | -27.40M | -34.98M | -43.45M | -58.92M |
| Pretax profit | -38.17M | -32.13M | -25.18M | -31.87M | -40.35M | -55.75M |
| Tax | 0 | 0 | -- | -- | 16.00K | 15.00K |
| Net profit | -38.17M | -32.13M | -25.18M | -31.93M | -40.37M | -55.77M |
| Basic EPS | -1 | -1 | 0 | -1 | -1 | -1 |
| Diluted EPS | -1.18 | -0.86 | -0.48 | -0.65 | -0.57 | -0.76 |
Balance sheet
| Line item | 2024 | 2025 |
|---|---|---|
| Total current assets | 69.65M | 348.82M |
| Cash & ST investments | 69.39M | 336.16M |
| Inventory | -- | -- |
| Total assets | 72.80M | 349.78M |
| Total current liabilities | 12.00M | 16.54M |
| Short-term debt | -- | -- |
| Long-term debt | 107.60M | -- |
| Total liabilities | 119,598,000.00 | 17,263,000.00 |
| Total equity | -46.80M | 332.52M |
| Retained earnings | -46.98M | -174.39M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 50.70M | 222.98M | 201.36M | 348.82M | 318.52M | 471.25M |
| Cash & ST investments | 49.93M | 220.94M | 198.91M | 336.16M | 311.30M | 461.21M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 56.32M | 223.97M | 202.45M | 349.78M | 319.43M | 472.11M |
| Total current liabilities | 16.05M | 21.62M | 22.36M | 16.54M | 22.29M | 31.57M |
| Short-term debt | -- | -- | -- | -- | -- | -- |
| Long-term debt | 123.00M | -- | -- | -- | -- | -- |
| Total liabilities | 139,834,000.00 | 22,412,000.00 | 23,104,000.00 | 17,263,000.00 | 22,971,000.00 | 32,198,000.00 |
| Total equity | -83.51M | 201.56M | 179.35M | 332.52M | 296.46M | 439.92M |
| Retained earnings | -85.15M | -117.28M | -142.46M | -174.39M | -214.76M | -270.52M |
Cash flow
| Line item | 2024 | 2025 |
|---|---|---|
| Operating cash flow | -- | -94.69M |
| Depreciation & amortization | -- | 26.00K |
| Free cash flow | -- | -94.89M |
| Dividends paid | -- | -- |
| Stock buybacks / issuance | -- | 189.11M |
| Ending cash balance | -- | 88.44M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -18.76M | -20.16M | -22.12M | -33.65M | -24.08M | -43.66M |
| Depreciation & amortization | 0 | 5.00K | 12.00K | 9.00K | 9.00K | 9.00K |
| Free cash flow | -18.76M | -20.30M | -22.18M | -33.65M | -24.08M | -43.66M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | 0 | -1.34M | -- | -- |
| Ending cash balance | 49.93M | 220.94M | 50.11M | 88.44M | 55.09M | 107.25M |
Returns & efficiency
| Line item | 2024 | 2025 |
|---|---|---|
| ROE %i | -- | -89.19 |
| ROA %i | -- | -60.30 |
| ROIC %i | -- | -67.79 |
| 5-year avg ROE %i | -- | -- |
| EBIT margin %i | -- | -- |
| FCF / sales %i | -- | -- |
| Current ratioi | 5.81 | 21.09 |
| Quick ratioi | 5.78 | 20.33 |
| Debt / assetsi | 147.80 | 0.21 |
| LT debt / equityi | -- | 0.22 |
| Interest coveragei | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- |
| Net income CAGR (3Y) %i | -- | -- |
| FCF CAGR (3Y) %i | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -- | -89.19 | -43.72 | -47.78 |
| ROA %i | -- | -- | -- | -60.30 | -40.57 | -44.03 |
| ROIC %i | -- | -- | -- | -67.79 | -45.69 | -49.85 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 3.16 | 10.31 | 9.01 | 21.09 | 14.29 | 14.93 |
| Quick ratioi | 3.11 | 10.22 | 8.90 | 20.33 | 13.96 | 14.61 |
| Debt / assetsi | 219.77 | 0.35 | 0.37 | 0.21 | 0.21 | 0.13 |
| LT debt / equityi | -- | 0.39 | 0.42 | 0.22 | 0.23 | 0.14 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Quote time 2026-10-08 08:46:53 · For reference only, not investment advice and not tailored to your situation.